TME PHARMA

- EUR (-)

- 15 min delayed data - Euronext Paris

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	ALTME
ISIN:	NL0015000YE1

TME PHARMA overview

> News Business Wire published a news.

TME Pharma Announces Poster Presentation by U.S. National Cancer Institute on CXCL12 Inhibition by NOX-A12 in Glioblastoma at 2024 SNO Annual Meeting • • Business Wire • Stocks • More TME PHARMA news...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the presentation of a poster featuring NOX-A12 data from preclinical studies performed at the U.S. National Cancer Institute (NCI) at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting, taking place in Houston, Texas, USA, November 21-24, 2024. The presentation showed...

Thank you Chart

> Analyses

Londinia AI has published a new analysis.

0
85460
15269
0

TME PHARMA - 1H

Timeframe : 1H - Simple chart
Status : INVALID

All elements being clearly bullish, it would be possible for traders to trade only long positions (at the time of purchase) on TME PHARMA as long as the price remains well above 0.3627 EUR. The…

Thank you Reply Chart

> Analyses

Londinia AI has published a new analysis.

0
85460
15269
0

TME PHARMA - 1H

Timeframe : 1H - Simple chart
Status : TARGET REACHED

TME PHARMA is currently trying to strengthen its basic trend with a very bullish short term. As long as the price remains above 0.3766 EUR, traders may consider taking advantage of this bullish…

Thank you Reply Chart

> Analyses

Londinia AI has published a new analysis.

0
85460
15269
0

TME PHARMA - 1H

Timeframe : 1H - Simple chart
Status : TARGET REACHED

The strong short-term increase in TME PHARMA calls into question the currently slightly bearish basic trend. A trend reversal is likely. As long as the price remains above 0.4597 EUR, you could…

Thank you Reply Chart

> News Business Wire published a news.

TME Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities • • Business Wire • Stocks • More TME PHARMA news...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME) , a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that pursuant to the liquidity contract entrusted to Invest Securities by TME Pharma N.V . the assets outlined below appeared on the liquidity account. The following assets appeared on the liquidity account as of June 30, 2023: Number of shares: 14,630 Cash balance of...

Thank you Chart

> News Business Wire published a news.

TME Pharma Provides Positive Data Update on Best Response to Therapy With First Complete Response in GLORIA Trial in Glioblastoma, Bringing 50% of Patients in Expansion Arm to Complete or Near-Complete Response • • Business Wire • Stocks • More TME PHARMA news...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces a positive clinical update on the best response to therapy, reporting one patient achieving complete response in the GLORIA expansion arm evaluating NOX-A12, TME Pharma's CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab, in first-line...

Thank you Chart

> News Business Wire published a news.

TME Pharma Announces Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma • • Business Wire • Stocks • More TME PHARMA news...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces a positive clinical update on the survival of first-line glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12, TME Pharma's CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab. After 15 months on study (median), 83% of GLORIA...

Thank you Chart

> News Business Wire published a news.

TME Pharma Receives Investigational New Drug (IND) Approval for NOX-A12 From the US FDA • • Business Wire • Stocks • More TME PHARMA news...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the US Food and Drug Administration (FDA), after reviewing the comprehensive submission, has approved the company’s Investigational New Drug (IND) application to evaluate the company’s lead asset NOX-A12 in a Phase 2 study in pancreatic cancer (OPTIMUS) in the United States....

Thank you Chart

Load more content